期刊文献+

美国药品质量抽查检验管理分析与启示 被引量:5

Analysis and Enlightenment of the American Drug Quality Sampling and Testing Management
原文传递
导出
摘要 目的分析美国药品质量抽查检验管理要点,为中国药品监督管理提供参考。方法采用文献研究法和数据分析法,通过相关文献和FDA官方网站等查找药品质量抽查检验相关文件,汇总2013—2017年抽查检验年报数据,研究美国药品质量抽查检验管理策略。结果美国药品质量抽查检验制定了抽查检验程序文件,建立了基于药品风险的品种遴选标准,注重质量监督检验和药品审评、监督检查的工作衔接与数据共享。结论美国药品质量抽查检验管理经验为中国推动监管科学研究、进一步提高药品抽检的科学性和靶向性提供参考。 OBJECTIVE To analyze the key points of American management of drug quality sampling and testing,and provide reference for the drug administration of China.METHODS Literature research and data analysis were conducted,relevant literatures were consulted,and the official website of FDA was retrieved to find documents related to drug quality sampling and testing,the data disclosed in the annual report of the drug sampling and testing between 2013 and 2017 were summarized,and the regulatory strategies revealed in American drug quality sampling and testing were researched.RESULTS The Compliance Program Guidance Manual for drug quality sampling and testing was established,the risk-based selection criteria was constructed,work cohesion seamless integration of surveillance,review,inspection and data sharing was emphasized in American.CONCLUSION The regulatory experiences of American drug quality sampling and testing,are still useful for the advancement of regulatory science,and further improvement of scientific and targeted nature of drug sampling and testing in China.
作者 王胜鹏 朱炯 王翀 WANG Shengpeng;ZHU Jiong;WANG Chong(National Institutes for Food and Drug Control,Beijing 100050,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2021年第5期630-635,共6页 Chinese Journal of Modern Applied Pharmacy
关键词 药品质量抽查检验 监管科学 上市后监管 经验启示 drug quality sampling and testing regulatory science post-marketing supervision experience and inspiration
  • 相关文献

参考文献4

二级参考文献37

  • 1郑文科,张俊华,杨丰文,王玉光,刘清泉,张伯礼.中医药防治新型冠状病毒肺炎各地诊疗方案综合分析[J].中医杂志,2020,61(4):277-280. 被引量:332
  • 2FDA. Information on adverse event reports and heparin [ EB/OL]. (2009 - 06 - 18 ). http ://www. fda. gov/Drugs/DrugSafety/Post- marketDrugSafetyInformationforPatientsandProviders/ucml 12669. htm.
  • 3FDA. Public Health Update : recall of heparin sodium for injection [ EB/OL ]. (2008 - 02 - 28 ). http ://www. fda. gov/Drugs/Drug- Safety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm 112665. htm.
  • 4FDA. Updated questions and answers on heparin sodium injection (Baxter) [ EB/OL]. (2008 -06 - 18 ). http://www, fda. gov/ Drugs/DrugSafety/PostmarketDrugSafetyln formationforPatientsand - Providers/ucm112606. htm.
  • 5FDA. FDA advises health care practitioners to switch suppliers and limit use of drug until problem identified [ EB/OL]. (2008 -02 - 11 ). http ://www. fda. gov/NewsEvents/Newsroom/PressAnnounce- ments/2008/ucm116858, htm.
  • 6FDA. Warning Letter: Changzhou SPL Company, Ltd. [ EB/OL]. ( 2008 - 04 - 21 ). http ://www. fda. gov/WarningLettersandNoti- ceofViolationLenerstoPharmaceuticalCompanies/UCM054109, pdf.
  • 7Contaminated heparin associated with adverse clinical events and activation of the contact system [ EB/OL]. (2008 -06 -05 ). ht- tp ://www. nejm. org/doi/full/10. 1056/NEJMoa0803200. html.
  • 8Oversulfated chondroitin sulfate is a contaminant in heparin associ- ated with adverse clinical events [ EB/OL ]. (2008 -04 -23 ). ht- tp://www, nature, com/nbt/journal/v26/n6/full/nbt1407, html.
  • 9USP. USP heparin information [ EB/OL ]. ( 2008 - 06 - 18 ). http :// www. usp. org/hottopics/heparin, html.
  • 10SFDA. Report for the reform of sampling test mode for drugs [R/OL]. 2006-03-20. http://www.315jj.com/article 106.aspx.

共引文献43

同被引文献39

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部